GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Formosa Laboratories Inc (TPE:4746) » Definitions » Debt-to-EBITDA

Formosa Laboratories (TPE:4746) Debt-to-EBITDA : 10.40 (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Formosa Laboratories Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Formosa Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$1,148 Mil. Formosa Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$2,752 Mil. Formosa Laboratories's annualized EBITDA for the quarter that ended in Dec. 2024 was NT$375 Mil. Formosa Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 10.39.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Formosa Laboratories's Debt-to-EBITDA or its related term are showing as below:

TPE:4746' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.18   Med: 4.79   Max: 9.79
Current: 5.24

During the past 13 years, the highest Debt-to-EBITDA Ratio of Formosa Laboratories was 9.79. The lowest was 1.18. And the median was 4.79.

TPE:4746's Debt-to-EBITDA is ranked worse than
81.16% of 674 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs TPE:4746: 5.24

Formosa Laboratories Debt-to-EBITDA Historical Data

The historical data trend for Formosa Laboratories's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formosa Laboratories Debt-to-EBITDA Chart

Formosa Laboratories Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.97 2.15 4.62 6.11 5.24

Formosa Laboratories Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.28 10.16 2.35 6.17 10.40

Competitive Comparison of Formosa Laboratories's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Formosa Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Formosa Laboratories's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Formosa Laboratories's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Formosa Laboratories's Debt-to-EBITDA falls into.


;
;

Formosa Laboratories Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Formosa Laboratories's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1148.109 + 2752.16) / 744.697
=5.24

Formosa Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1148.109 + 2752.16) / 375.22
=10.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Formosa Laboratories  (TPE:4746) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Formosa Laboratories Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Formosa Laboratories's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Formosa Laboratories Business Description

Traded in Other Exchanges
N/A
Address
No. 36-1, Hoping Street, Louchu, Taoyuan, TWN, 33842
Formosa Laboratories Inc is mainly engaged in the wholesale and manufacturing of active pharmaceutical ingredients, as well as ultraviolet absorbers. The company geographically operates in India, Taiwan, Netherlands, Switzerland, Germany, Japan, China, Canada, United States, Spain and Others.

Formosa Laboratories Headlines

No Headlines